Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Factor VIII 1,000unit/vWf 600unit inj vials
0211000I0AABGBG
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Factor VIII 250unit /von Willebrand factor 430unit inf vials
0211000I0AABCBC
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Factor VIII 500u / von Willebrand factor 1,200unit inj vials
0211000I0AAABAB
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Factor VIII 500unit /von Willebrand factor 860unit inf vials
0211000I0AAAWAW
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Factor VIII 500unit/von Willebrand factor 300unit inj vials
0211000I0AABFBF
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Factor VIII Inhibitor Bypassing Fraction hum 1,000unit inf
0211000Y0AAAAAA
|
Factor VIII Inhibitor Bypass Fraction | Factor VIII Inhibitor Bypass Fraction | Cardiovascular System | No data available |
|
Factor XIII 1,250unit inj vials
0211000U0AAABAB
|
Dried Factor XIII Fraction | Dried factor XIII fraction | Cardiovascular System | No data available |
|
Factor XIII 250unit inj vials
0211000U0AAAAAA
|
Dried Factor XIII Fraction | Dried factor XIII fraction | Cardiovascular System | No data available |
|
Fanhdi 1,000unit inj vials
0211000I0BPAAAD
|
Fanhdi | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Fanhdi 500unit inj vials
0211000I0BPABAC
|
Fanhdi | Dried factor VIII fraction | Cardiovascular System | No data available |
|
FEIBA 50units/ml (1,000unit) pdr and 20ml solvent inf vials
0211000Y0BBAAAA
|
FEIBA | Factor VIII Inhibitor Bypass Fraction | Cardiovascular System | No data available |
|
Felodipine 2.5mg/5ml oral solution
0206020F0AAAGAG
|
Felodipine | Felodipine | Cardiovascular System | No data available |
|
Felodipine 2.5mg/5ml oral suspension
0206020F0AAAIAI
|
Felodipine | Felodipine | Cardiovascular System | No data available |
|
Felodipine 5mg/5ml oral solution
0206020F0AAAHAH
|
Felodipine | Felodipine | Cardiovascular System | No data available |
|
Felogen XL 10mg tablets
0206020F0BFABAC
|
Felogen | Felodipine | Cardiovascular System | No data available |
|
Felogen XL 5mg tablets
0206020F0BFAAAB
|
Felogen | Felodipine | Cardiovascular System | No data available |
|
Fenofibrate 160mg/5ml oral solution
0212000P0AAAGAG
|
Fenofibrate | Fenofibrate | Cardiovascular System | No data available |
|
Fenogal 200mg capsules
0212000P0BDAAAF
|
Fenogal | Fenofibrate | Cardiovascular System | No data available |
|
Fibrase 50mg capsules
0208020I0BBAAAB
|
Fibrase (Oral) | Pentosan polysulfate sodium | Cardiovascular System | No data available |
|
Fibro-Vein 0.2% solution for injection 5ml vials
0213000T0BDABAH
|
Fibro-Vein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibro-Vein 0.5% solution for injection 2ml ampoules
0213000T0BDAAAC
|
Fibro-Vein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibro-Vein 1% solution for injection 2ml ampoules
0213000T0BDACAD
|
Fibro-Vein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibro-Vein 3% solution for injection 2ml ampoules
0213000T0BDADAF
|
Fibro-Vein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibro-Vein 3% solution for injection 5ml vials
0213000T0BDAEAG
|
Fibro-Vein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibrogammin 1,250unit inj vials
0211000U0BBABAB
|
Fibrogammin | Dried factor XIII fraction | Cardiovascular System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.